FDA WARNING_LETTER - Las Villas Health Care LLC dba Villas Health - August 01, 2025

On September 9, 2025, the FDA issued a warning letter to Las Villas Health Care LLC, operating as Villas Health, following a review of the company"s website in August 2025. The investigation revealed significant violations of the Federal Food, Drug, and Cosmetic Act regarding the marketing of compounded semaglutide and sildenafil products. The primary issue is that Villas Health made false or misleading claims that equated their compounded versions with FDA-approved drugs such as Ozempic, Wegovy, and Viagra. Because compounded drugs do not undergo the same FDA approval process as brand-name medications, suggesting they are identical is considered misbranding under federal law. The agency specifically noted that the company"s promotional materials improperly suggested proven clinical outcomes and equivalent active ingredients. To resolve these issues, the FDA requires Villas Health to take immediate corrective action, including removing the misleading claims from their website. The company must submit a written response within 15 working days detailing their corrective plan and the steps they are taking to ensure future compliance. Failure to address these violations promptly could result in legal consequences such as product seizures or injunctions.